In this national centralized procurement, the price of cochlear implant-related consumables (including the implant and speech processor) has dropped from an average of over 200,000 yuan to around 0.05 million yuan. After the price reduction, how to ensure a reasonable profit margin for companies? Lu Dawei, director of the Technical Regulations Department of the China Medical Instrument Industry Association, stated that selected enterprises highly value the large market behind national centralized procurement. Currently, 80% of the patients undergoing cochlear implant surgeries are children, while only 20% are adults. In the future, the proportion of elderly patients receiving cochlear implants will continuously increase. 'Calculating from the perspective of price and quantity, selling one product at a High Stock Price and selling ten products at a lower price will yield the same revenue, but after the price reduction, the market scale will expand. This is a key consideration for companies,' Lu Dawei said. A relevant person from the Ministry of Industry and Information Technology stated that they will continue to carry out dynamic monitoring of national centralized procurement products, promptly identify and coordinate the resolution of potential issues that may affect production and supply, and ensure that selected products can be stably supplied to the market. They will urge enterprises to improve the production and supply of selected products, support enterprises in carrying out technological transformation, and enhance supply guarantee capabilities.